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Abstract
Introduction:  Pseudocholinesterase (butyrylcholinesterase) is a drug metabolizing enzyme
responsible for hydrolysis of the muscle relaxant drugs succinylcholine and mivacurium. Deficiency
from any cause can lead to prolonged apnoea and paralysis following administration of
succinylcholine and mivacurium.
Case presentation: Within the last two years we have had four patients who have had prolonged
apnea following the administration of mivacurium. It was understood that one was congenital and
the other three due to various reasons had enzyme-deficiencies. In all four of the patients, the
prolonged blocks deteriorated.
Conclusion: Prolonged blocks may be encountered due to mivacurium use. The diagnosis of
pseudocholinesterase enzyme deficiency can be given after a careful clinic supervision and
peripheral nerve stimulator monitoring. A decrease in the activity of pseudocholinesterase enzyme
and improvement in neuromuscular function will help verifying our diagnosis. Instead of
pharmacological applications that may further complicate the situation, what should be done in
such patients is to wait until the block-effect goes down by the help of sedation and mechanical
ventilation.
Introduction
Pseudocholinesterase (PChE) is an enzyme with a com-
plex molecular structure [1]. It is synthesized in the liver
and immediately released into the plasma [2]. The plasma
half-life has been estimated to be approximately 12 days
[3]. Deficiency or reduced activity of this enzyme results in
significant prolongation of mivacurium or succinylcho-
line induced neuromuscular blockade [4]. In addition,
PChE activity may be reduced by a number of disease
states or by concomitant drug administration.
Mivacurium, which is a nondepolarizing neuromuscular
blocking drug administered in doses of 0.1 to 0.2 mg/kg,
also produces rapid onset of neuromuscular blockade
lasting 15 to 30 minutes [5]. The rapid ester hydrolysis of
mivacurium by PChE results in the short duration of
action of this drug, which is ideal for providing muscle
relaxation for brief surgical procedures [6]. But, the dura-
tion of mivacurium in adults is inversely related to serum
PChE activity [7].
In this article, we would like to share our experiences in
the management of four patients who developed mivacu-
rium apnea postoperatively due to congenital or acquired
pseudocholinesterase enzyme deficiencies alongwith a lit-
erature review.
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Case presentation*
Patient 1
A 31-year-old Turkish woman, weighing 78 kg, was sched-
uled for caesarean section under general anesthesia. She
was not operated previously. Induction of anesthesia was
achieved with 130 mg of propofol. Muscular relaxation
was achieved before intubation with 12 mg of mivacu-
rium. Isoflurane was used as the general anesthetic inha-
lation agent. The operation lasted for 30 minutes and the
sectio-surgery was uneventful. After the surgery, the inha-
lation agent was discontinued and the patient received
100% oxygen. It was noted that emergence seemed to be
prolonged after 10 minutes. All vital signs were stable,
showing no signs of tachycardia or hypertension. Oxygen
saturation remained 100%. After an additional 10 min-
utes, there was suspicion of a PChE deficiency. Peripheral
nerve stimulator (PNS) produced zero twitches. Three
milligrams of midazolam was administered intravenously
for its sedation and amnestic effects. Later the patient was
transferred to the post-anesthesia Care Unit (PACU) for
observation and ventilator support. Sixty-two minutes
later, spontaneous muscle twitching was noted. One hour
and twenty-two minutes later from the initial use of miva-
curium, the patient had regained sufficient motor func-
tion to meet extubation requirements. Blood samples
were drawn and sent to confirm a PChE deficiency [Pait-
ent's PChE value (normal range) 1017 IU/L (2000 to
11000 IU/L)]. The patient was transferred to a hospital
ward for the evening and discharged two days later. The
PChE values of the patient who was called for a control
after two months was considered between the normal
ranges (3124 IU/L).
Patient 2
A 47 year-old Turkish male, weighing 83 kg, was sched-
uled for laparoscopic cholecystectomy under general
anesthesia. The patient had received two previous general
anesthetics one for appendectomy 28 years ago and
another for right inguinal hernia operation 19 years ago.
It was learned that the case was applied succinylcholine
during both of her previous operations and that he did
not have a a history of a post-operative apnea etc. The
patient had been using sertraline (100 mg/day) for 3 years
due to major depressive disorder. Induction of anesthesia
was achieved with 200 mg of propofol. Tracheal intuba-
tion was achieved with 17 mg of mivacurium. Isoflurane
was used as the general anesthetic inhalation agent. The
operation lasted for 25 minutes and further dose(s) of
mivacurium were not required. After the surgery, the inha-
lation agent was discontinued, the patient received 100%
oxygen but PNS produced zero twitches. All vital signs
were stable, and oxygen saturation remained 100%. After
an additional 20 minutes, there was suspicion of a PChE
deficiency. Five milligrams of midazolam was adminis-
tered intravenously for its sedative and amnestic effects.
Later the patient was transferred to the PACU for observa-
tion and ventilator support. Two hours and twenty min-
utes later, spontaneous muscle twitching was noted. Three
hours and fifteen minutes later from the initial use of
mivacurium, the patient had regained sufficient motor
function to meet extubation requirements. Plasma
cholinesterase was found to have very low activity (788
IU/L). The patient was transferred to a hospital ward for
the evening and discharged four days later.
Patient 3
A 73 year-old Turkish woman, weighing 43 kg, was sched-
uled for breast biopsy under general anesthesia. She had a
cholecystectomy 32 years ago, a hysterectomy 23 years
ago and an appendectomy operation 17 years ago. It was
learned from the anamnesis of the patient that succinyl-
choline had been administered on three previous occa-
sions during anesthesia without a prolonged effect.
Following preoxygenation, induction of anesthesia was
achieved using propofol 90 mg and later mivacurium 7
mg. Following tracheal intubation anesthesia was main-
tained with isoflurane. The procedure was completed
within 20 minutes. But there was no clinical evidence of
recovery of neuromuscular function and there was no
response to train of four stimulation. Anesthesia was
therefore maintained with isoflurane 0.5% in 50%
nitrous oxide and oxygen. Because there was no evidence
of improved neuromuscular function 60 minutes after
administration of mivacurium. The patient was trans-
ferred to the PACU for continued mechanical ventilation
and neuromuscular monitoring. Sedation was main-
tained with a continuous iv infusion of midazolam. Four
hours and twenty minutes after the administration of
mivacurium, train of four response ratio was 75%. Mida-
zolam infusion was discontinued and clinical assessment
confirmed recovery of neuromuscular function. Patient
was extubated 340 minutes following the administration
of mivacurium and further recovery was uneventful.
Plasma cholinesterase was found to have very low activity
(598 IU/L).
Patient 4
A 28 year-old Turkish male, weighing 76 kg, was sched-
uled for unilateral varicocelectomy and hydrocelectomy
under general anesthesia. The patient did not have an
operation previously. Induction of anesthesia was
achieved with 200 mg of propofol. Tracheal intubation
was achieved with 15 mg of mivacurium. Isoflurane was
used as the general anesthetic inhalation agent. The oper-
ation was completed within 30 minutes. After the surgery,
the inhalation agent was discontinued and the patient
received 100% oxygen. All vital signs were stable, oxygen
saturation remained 100%, but PNS produced zero
twitches. After an additional 10 minutes, there was suspi-
cion of a PChE deficiency. Three milligrams of midazolamCases Journal 2009, 2:9148 http://www.casesjournal.com/content/2/1/9148
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was administered intravenously for its sedative and
amnestic effects. Fifty-five minutes later, spontaneous
muscle twitching was noted. One hour and five minutes
after the initial use of mivacurium, the patient had
regained sufficient motor function to meet extubation
requirements. Plasma cholinesterase was found to have
low activity (961 IU/L). The patient was transferred to a
hospital ward for the evening and discharged two days
later.
*(Monitoring included electrocardiography (ECG), non-
invasive arterial blood pressure (NIBP), oxygen saturation
(SpO2), capnography (ETCO2), and peripheral nerve
stimulator monitoring applied over the ulnar nerve in all
four patients)
Discussion
Mivacurium is a potent benzylisoquinoline, nondepolar-
izing neuromuscular blocking drug. A recommended
intravenous dose of 0.15 to 0.2 mg/kg provides tracheal
intubating conditions within 2 to 2.5 minutes, with a pre-
dicted duration of action of 15 to 25 minutes, making it
an ideal drug for short procedures requiring tracheal intu-
bation [8]. İt is a structural relative of atracurium, but it
does not undergo Hofmann elimination and is rapidly
hydrolysed by PChE. Its duration of action is affected by
the activity of this enzyme.
PChE is a tetrameric glycoprotein enzyme produced by
the liver that hydrolyzes choline esters, such as those
found in succinylcholine, mivacurium, procaine, chloro-
procaine, tetracaine, cocaine and heroine [9]. In patients
with a normal genotype for PChE, mivacurium's duration
of action is inversely related to PChE activity and duration
of action is slightly prolonged if activity is low [10].
Reduced PChE activity may occur as a result of inherited
causes related to mutations at a single autosomal location
on the long arm of chromosome 3 [11].
When there is a deficiency of this enzyme due to the pres-
ence of one or more atypical alleles, the mivacurium is not
properly metabolized and thus, muscle paralysis can last
for several hours. There are two forms of inherited atypical
pseudocholinesterase deficiency. The heterozygous atypi-
cal form affects anywhere from 1 in 25, to 1 in 480 indi-
viduals (depending on the severity of the condition) [9].
Patients heterozygous for an abnormal enzyme may show
up to 50% prolongation of block [12]. The homozygous
atypical form affecting approximately 1 in 3200 to 5000
individuals [9]. In patients homozygous for an abnormal
enzyme duration may be significantly prolonged, and
even a small dose, (eg.0.03 mg/kg) can result in complete
paralysis for up to 128 minutes [13]. Patient 4 did not
have an operation previously as well, he also did not have
a negative medical family history and he did not accept
our spinal anaesthesia offer. Block time was prolonged by
30-35 minutes which did not require a post-operative care
unit. Enzyme level was found to be slightly low (961 UI/
L). And the case was considered as heterozygote atypic
enzyme defected.
PChE activity may be affected by different disease states
and/or by drug administrations. Physiologic reductions
may occur with extremes of age and during pregnancy
[14]. The low enzyme value (1017 IU/L) of Patient 1
which was measured during her cesarean section opera-
tion was found to be within the normal ranges in the lab-
oratory assessment carried out during the control after
two months (3124 IU/L) which proved us right in think-
ing that the PChE deficiency was due to pregnancy.
Other acquired causes of decreased activity include renal
and liver disease, malignancy, burns, chronic debilitation/
malnutrition, myocardial infarction/cardiac failure, colla-
gen diseases, myxedema, and organophosphate poison-
ing [14]. Patient 3 previously had three operations under
general anaesthesia by using succinylcholine. Renal func-
tion was normal in this patient. Liver function tests
exposed a reduced albumin level (2.1 g/dL = 21 g/L), con-
sistent with the diagnosis of malnutrition that was evident
from patient's general cachectic appearance (weighing
only 43 kg), and history of reduced caloric intake and
recent weight loss. However, presence of a prolonged
apnea and low enzyme activity (598 IU/L) in this opera-
tion although the case had not had any problems during
the previous operations led us to think that this was a mal-
nutrition-associated PChE deficiency. Actually, plasma
cholinesterase levels in human subjects with protein
energy malnutrition has been investigated [15]. PChE
deficiency secondary to malnutrition has also been
reported in patients with active Crohn's disease [16], and
anorexia nervosa [17].
In addition, drugs which inhibit the enzyme's activity
include acetylcholinesterase inhibitors (neostigmine,
pyridostigmine, physostigmine, and edrophonium) anti-
cholinesterases (especially echothlophate), cytotoxic
agents (such as cyclophosphamide), steroids, ester-type
local anaesthetics, hexafluorenium, pancuronium and
oral contraceptives [18].
Sertraline is a serotonin reuptake inhibitor (SSRI) that is
indicated for the treatment of depression. With therapeu-
tic doses, side effects are minimal. Sertraline has a wide
therapeutic index and appears to be safer than the tricyclic
antidepressants in overdose [19]. On the other hand, the
usual clinical antidepressants (fluoxetine, sertraline, and
amitriptyline) are inhibitors of the cholinesterases on
human serum and erythrocyte membrane. The order of
inhibitory potency was sertraline> amitriptyline>>fluoxe-Cases Journal 2009, 2:9148 http://www.casesjournal.com/content/2/1/9148
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tine [20]. Our Patient 2 patient had been using sertraline
(100 mg/day) for 3 years due to depression. He previously
had three operations under general anaesthesia by using
succinylcholine. However, presence of a prolonged apnea
and low enzyme activity (788 IU/L) in this operation,
although the case had not had any problems during the
previous operations led us to think that this was a serta-
line-associated acquired PChE deficiency. Besides, the re-
tested (3 months after the operation) PChE value (2762
IU/L) was seen to have turned back to normal after the
patient gave up using sertraline under psychiatrist control.
We did not discover a case that implies an interaction
between sertraline and pseudocholinesterase in our litera-
ture review. We believe this is the first case presentation in
that sense.
Mivacurium should probably not be used for any patient
who gives a history of prolonged block after succinylcho-
line. Any patient who experiences prolonged block after
mivacurium should be advised on the need to have their
own and their immediate family's plasma cholinesterase
status checked. It was detected from the blood-samples
received from the first-degree relatives of Patient 4 that
PChE activities of them were also lower than 900 IU/L,
and however that incidentally none of them had opera-
tion histories.
The clinician should be aware that if they have adminis-
tered neostigmine to a patient with prolonged mivacu-
rium-induced block, then the patient's plasma
cholinesterase activity will be inhibited. Therefore, blood
should not be drawn for cholinesterase activity until the
effect of neostigmine has dissipated. As for four of our
cases, by the time PChE defect suspicions alongwith PNS
findings arose, we send blood samples to laboratory for
enzyme values. We supported the cases for degradation of
mivacurium with present enzyme activities solely with
sedation, mechanical ventilation and PNS monitorization
and without neostigmine application.
Conclusion
We may find out that prolonged blocks can be encoun-
tered as a result of PChE enzyme defect when mivacurium
is used. This situation can either be from congenital as in
one of our patients (Patient 4) or due to various resons
(pregnancy, malnutrition and sertraline use) as in the
other three patients.
In these situations, attempted reversal of the block was at
best only partially successful, and the patients were par-
tially paralysed and minimally sedated while attempts
were made to have them breathe; a very unpleasant expe-
rience. In the cases of prolonged block, no reversal was
attempted, the cases were kept sedated and their lungs
mechanically ventilated until the block had recovered
spontaneously, and then extubated without problems.
This patient had a much less traumatic experience than
the others, in whom pharmacological reversal was
attempted.
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